June 2, 2026

From Crisis to Prevention: Using Artificial Intelligence to Identify Youth at Risk for Psychiatric Illness
Jonathan Posner, M.D.
Tuesday, June 2, 12-1 p.m.

Learning objectives:

• Describe limitations of current, symptom-based approaches to identifying youth at risk for psychiatric illness.
• Understand how longitudinal clinical and behavioral data can be used to forecast future mental health risk.
• Recognize how AI-derived risk models can highlight individualized, modifiable pathways (e.g., sleep, family stress) to inform preventive intervention.
• Discuss opportunities and challenges in implementing scalable mental health risk screening within primary care.

May 19, 2026

Psychiatry and Moral Bioenhancement: The Case of Psychopathy
Fabrice Jotterand, Ph.D., M.A.
Tuesday, May 19, 12-1 p.m.

Learning objectives:

• Define and contextualize the concept of moral bioenhancement within both the clinical setting and the broader social context.
• Outline potential novel applications of neurotechnology in psychiatry for the treatment of individuals suffering from mental disorders with moral pathologies.
• Assess the feasibility, utility, and limitations of moral bioenhancement techniques for the diagnosis and treatment of individuals exhibiting psychopathic traits.

May 5, 2026

Emerging Neuropsychopharmacology: Orexin Antagonists and Novel Agents-Indications Across the Psychiatric Spectrum
Aaron Stringfield, Pharm.D., BCPP
Tuesday, May 5, 12-1 p.m.

Learning objectives:

Part 1: Dual Orexin Receptor Antagonists (DORAs)

• Describe the mechanism of action of dual orexin receptor antagonists and explain how selective inhibition of orexinergic neurotransmission promotes sleep without disrupting normal sleep architecture.
• Compare the pharmacokinetic profiles of suvorexant, lemborexant, and daridorexant, including half-life differences, and apply this knowledge to patient selection and dosing strategies.
• Evaluate the comparative efficacy of the three FDA-approved DORAs for subjective sleep onset latency and total sleep time.
• Contrast the safety profile of DORAs with traditional GABAergic hypnotics, particularly regarding next-day residual effects, cognitive impairment, dependence potential, and tolerance.
• Identify clinical scenarios where DORAs are preferred over other insomnia treatments, including consideration of comorbid psychiatric conditions and contraindications (e.g., narcolepsy with cataplexy).

Part 2: Novel Psychotropic Agents and Indications

• Explain the unique muscarinic mechanism of xanomeline/trospium (Cobenfy/KarXT) as the first non-dopaminergic antipsychotic for schizophrenia and describe its efficacy and tolerability profile.
• Describe the evidence base for lumateperone as FDA-approved adjunctive therapy in major depressive disorder, including its mechanism of action for treating depression
• Discuss the clinical applications of esketamine for treatment-resistant depression and acute suicidal ideation, including its NMDA receptor antagonism mechanism and both monotherapy and adjunctive use.
• Identify the clinical significance of brexpiprazole as the first FDA-approved treatment for agitation associated with dementia due to Alzheimer's disease, including its efficacy profile and safety considerations in elderly patients.
• Compare zuranolone and brexanolone for postpartum depression, emphasizing the practical advantages of the 14-day oral formulation (zuranolone) versus the 60-hour IV infusion (brexanolone, now discontinued)

April 21, 2026

Introduction to Internal Family Systems
Richard Schwartz, Ph.D.
Tuesday, Apr. 21, 12-1 p.m.

Learning objectives:

• Define and differentiate the primary categories of parts within the IFS framework: Managers, Firefighters, and Exiles.
• Describe the concept of Self in IFS, including its defining qualities and its central role in healing and integration.
• Explain the developmental origins of parts and their relationship to stress, trauma, and adaptation.
• Analyze how IFS conceptualizes psychological symptoms as adaptive responses rather than pathology.
• Demonstrate an introductory capacity to identify parts and observe their interactions within the internal system.
• Apply basic IFS-informed inquiry techniques, such as un-blending and cultivating curiosity toward parts. 

March 31, 2026

Bipolar Depression: Strategies to Improve Identification and Treatment
Julie Anderson, M.D.
Tuesday, Mar. 31, 12-1 p.m.

Learning objectives:

• Describe extent of unidentified bipolar disorder in clinical settings and implications clinically in the treatment of "depression".
• Provide more effective screening strategies to identify bipolarity where the standard clinical approach of asking about DSM criteria for past mania often fails.
• Identify impact of augmentation with antidepressants vs placebo on treatment outcomes for bipolar depression both acutely (6-8 weeks) and chronically.
• Analyze the evidence-base for treatment of bipolar depression to establish fundamental principles underlying best practices in treatment of depressed patients on the bipolar spectrum.

March 17, 2026

Let’s Talk about Sex: Dating and Intimacy for Patients with Intellectual and Developmental Disability 
Nina Bihani, M.D.
Tuesday, Mar. 17, 12-1 p.m.

Learning objectives:

• Explain how to assess capacity for consent in patients with intellectual & development disability.
• Analyze how to discuss issues of dating, sexuality, and sexual safety with patients with intellectual and developmental disabilities. 
• Explore the ethics of consent and decision-making with regards to this patient population.

March 3, 2026

Catatonia in the Context of Anti-NMDA Encephalitis: Describing an ECT-Resistant Case and Emphasizing the Medical Etiology of Catatonia 
Jacqueline Koichi, D.O.
Tuesday, Mar. 3, 12-1 p.m.

Learning objectives:

• Discuss medical vs psychiatric subtypes of catatonia.
• Recognize key predictors suggesting catatonia due to a medical condition. 
• Compare treatment response and hospital outcomes between subtypes.
• Explore optimization of care through early identification of the catatonia subtype. 

Grand Rounds Notifications

We send out notifications a few days in advance of Grand Rounds. If you would like to receive these notifications or receive an error, please email psych@ohsu.edu 

Watch Grand Rounds Live!

Use Google Chrome browser to access the live stream of Psychiatry Grand Rounds. If the button link below does not work, try to manually copy and paste the following link into a new google chrome window: https://echo360.org/section/faa3b8a4-7bd6-424e-b7a7-2d7e96f6be51/public

Past presentations

To view past presentation recordings, please visit our archived videos page. You will need to use google chrome browser.

Apply to present at Psychiatry Grand Rounds

If you would like to make a presentation at Psychiatry Grand Rounds, please fill out one of our applications at the link below. Our committee will review the material and if it is a good fit for our program, we will reach out to you with available dates.

Receiving CME

OHSU CME credits for physicians are now available in CME Passport. CME Passport is a free, centralized web application that enables physicians to view, track, and generate transcripts of their reported CME credits. For more information, please visit the Accreditation Council for Continuing Medical Education CME Passport Information for Providers page.  

To access your OHSU CME transcript, please visit the CME tracker.

Please follow the link below to fill out an evaluation survey to receive credit for participating in Psychiatry Grand Rounds. The survey will not allow you to submit attendance more than 10 days past the date of the presentation.

Typically held the 1st and 3rd Tuesdays of each month

Psychiatry Grand Rounds provides continuing medical education for the public. We strive to enable discussion that is both about and involves the patient so the physician can better understand the depth of one's mental illness. In Psychiatry Grand Rounds, we explore the history of certain policies and procedures in place for handling mentally ill patients and what can happen to improve care and treatment that they receive, as well as to better explain and expand on various forms of mental illness and how treatment should be approached and practiced by the clinician.

Accessing psychiatry grand rounds remotely

Our lectures are accessible to be viewed remotely. (Use Google Chrome Browser) 

To receive CME credit, you must watch the lecture either live during the time of the presentation or from our archived presentations. After you watch the Grand Rounds, you can submit your attendance by filling out an evaluation survey, the link to which is given in the above section labeled "Receiving CME". The survey will not allow you to submit attendance more than 10 days past the date of the presentation. You can sign up for the announcements below. If you have any questions please contact the Grand Rounds Coordinator, Charlotte Heard, at psych@ohsu.edu.  

Grand rounds committee members

• Karim Afzal
• Cem Batuman
• Jonathan Betlinski
• Chris Blazes
• Charlotte Heard
• Andrea Hughes
• George Keepers
• Sheldon Levy
• Maya Lopez
• Eva Mathews
• Lisa Schimmel
• Craigan Usher
• Nadia Wahba

Accreditation

Oregon Health & Science University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit

OHSU School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target audience

Psychiatrists, psychologists, psychiatry residents and fellows, medical students, social workers, master's in administration, physician assistants, nurse practitioners, nurses, pharmacists, and all physicians. Additionally, Psychiatry Grand Rounds is open to the public.